1.. Introduction
Thee neurohypopyseal peptide hormone AVP is known to regulate the water reabsorptionn in the renal collecting duct via the V 2 receptor 1 and to potently constrictt numerous vascular beds through the Vi receptor 2 . Furthermore AVP appearss to mediate vasodilation in some vascular beds through the V 2 receptor 3 " 5 .. AVP also exerts haemostatic activity, via enhanced platelet aggregation 6 andd an increased release of coagulation factors 7 . Moreover AVP regulates the releasee of adrenocorticotropic hormone (ACTH), through activation of the V 3 -pituitaryy receptor (or Vib) 8 .
Elevatedd plasma AVP levels are a common finding in congestive heart failure 9;100 and this could play a role in the pathophysiology of this syndrome. Several studiess have evaluated a possible role of AVP in essential hypertension. These analysess did not yield conclusive results, but it is plausible that AVP may play aa pathophysiological role in subgroups of hypertensive subjects n " 13 . Until now thee role of AVP is not straightforward, one explanation is the heterogeneity of responsess in different vascular beds. These range from a strong vasoconstriction,, to vasodilation and even to a biphasic vascular response in thee human forearm 14~16 .
Duee to its function in body homeostasis the renal vascular bed is important in thee development of congestive heart failure and hypertension. Previous studiess demonstrated that the vasoconstrictive action of AVP is attenuated by manyy factors in the renal vasculature. In vivo there is evidence for an interactionn between AVP and the sympathetic nervous system 17 . A second majorr aspect is the possible vasodilator role of the V 2 receptor, thus attenuatingg the vasoconstrictive action of the Vi receptor 18~20 . A third importantt factor is the interaction between the vascular smooth muscle cells andd the endothelium 21;22 . Although all these mechanisms are known to be involvedd in the interaction between AVP induced vascular smooth muscle cell contractionss and the endothelium, their relative contributions are not clear. Thiss point is even more essential because our first experiments evaluate this thirdd point, showed the involvement of an unknown endothelium dependent factorr that increases the AVP-induced contractile response.
Thee objective of the present study is to identify the nature and its contribution off AVP to the regulation of the rabbit renal artery resistance by functional pharmacologicall means. Furthermore the relative contributions of the NO, cyclooxygenasee and lipoxygenase pathways were assessed. The subtypes of thee AVP receptors involved were identified by the use of selective agonists and antagonists,, respectively. Additional experiments were performed to determinee the interaction with the intermediate and large conductance Ca 2+ activatedd K + channels and the endothelin system with AVP. (25) at room temperature, which was continuously gassed with carbogenn (95% 0 2 and 5% C0 2 ). The vessels were cleaned of superficial fat andd connective tissue. Care was taken not to stretch the vessels or to damage thee endothelium. The renal artery rings were cut into segments of approximatelyy 3 mm long each, and mounted between two triangular stainless steell hooks and put into organ baths containing 5 ml PSS at . The mixturee was continuously gassed with carbogen. Ring preparations were studiedd with and without endothelium. The endothelium was removed by carefullyy rubbing the luminal surface with a steel rod. Isometric tension was measuredd by means of isometric force transducers (A.D. instruments, Castle Hill,, Australia), connected to a MacLab/8 computer system. The vessel rings weree equilibrated in PSS for 30 min at a resting tension of 2.0 g, which was maintainedd throughout the experiment.
2.. Methods

RenalRenal artery ring preparations
ExperimentalExperimental protocol
Afterr the equilibration period the renal artery rings were exposed for 5 min to aa depolarising PSS (containing 60 mM K + ), thus causing a contraction of the vascularr smooth muscle. In this solution 55.3 mM NaCI has been isotonically replacedd by KCI, resulting in a total KCI concentration of 60 mM. With 20 min equilibrationn intervals this was followed by 5 min periods of additional exposuree to PSS KCI 60 mM. This procedure was followed by vasoconstriction, inducedd by phenylephrine (PhE) 0.3 uM, after which the endothelial-function wass tested by means of methacholine (MCh; 0.3, 1 and 3 uM, respectively). Preparationss with an E ma x less than 80 % were considered too much damaged forr the experiment and discarded. In preparations were the endothelium was removedd the E max was less than 20 % or the vessels were discarded. Subsequently,, after 30 minutes PSS KCI 60 mM was applied again. Thirty minutess after the last potassium-induced contraction, a cumulative concentration-contractilee response curve for vasopressin or desmopressin was constructedd in each ring. The concentrations were successively increased, at thee moment the increase of contractile force stabilised or after 30 seconds in casee of no functional effect of the concentration under investigation. The influencee of endothelium dependent factors and vasopressin-receptor selectivityy was evaluated in separate set of experiments, with a comparable experimentall protocol until the third potassium-induced contraction. Directly afterr this contraction our vessel strips were incubated for 30-minute period withh one of the following, substances: L-NNA, charybdotoxin, indomethacin, SRR 49059, or SR 121463 B. Thereafter, in the presence of this substance, a concentrationn response curve to vasopressin was constructed.
DrugsDrugs and chemicals used L-phenylephrinee hydrochloride, L-NNA (N-Nitro-I-Arginine) and, acetyl-p methacholinee were obtained from Sigma (St. louis, USA). (Arg8)-AVP, Desmopressinn and Charybdotoxin were obtained from Bachem (Bubendorf, Switzerland).. Meclofenamic acid was obtained from ICN (Aurora, USA). Bosentann was a gift from Actelion Pharmaceuticals (Allschwil, Switzerland). All thesee drugs were dissolved in distilled water. Both SR-49059 and SR-121463 BB were gifts of Sanofi (Toulouse, France). SR-49059 and SR-121463 B were dissolvedd in 100% DMSO to a concentration of 1 mM, and the solution was subsequentlyy diluted with distilled water to the final concentration needed. Indomethacinn was purchased from Merck Sharp and Dohme (Haarlem, Netherlands)) and it was dissolved in a solution of NaOH 1 M Na 2 C0 3 0.1 M to a concentrationn of 10 mM, and subsequently further diluted with distilled water too the final concentration needed.
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EvaluationEvaluation of data
Thee data are expressed as means S.E.M. The concentration-response curves forr the compounds investigated were analyzed by means of a computer programmee (Graph Pad, Institute for Scientific Informatics, San Diego, CA, U.S.A.).. The pD 2 -value [-log of the effective concentration (molar) that producess 50% of the maximal effect (EC 50 )], as well as the maximal effect (E max )) were thus obtained from the non-linear regression curve fit analysis for thee individual experiments. The statistical significance of the differences was evaluatedd using a one-way analysis of variance followed by a Bonferroni posttest.. Values of P<0.05 were considered significant.
3.. Results
Ass shown in figure 1, AVP induced, in vessels with intact endothelium, a maximall contraction of 1 mN, with a pD 2 of . Inhibition of the endotheliall NO synthesis by N-Nitro-L-Arginine (L-NNA) 10 uM resulted in an E maxx increase to 8 mN (p<0.05) and a comparable pD 2 of .
Removall of the endothelium did not result in the same increase in E max , but showedd a comparable response (E max 3 mN) to the vessels with intact endothelium.. The potency remained the same (pD 2 : .
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4.. Discussion
Wee investigated the role of AVP and its interaction with the endothelium and thee vascular tissue of the rabbit renal artery. AVP is known to stimulate the releasee of NO in the renal circulation 18;23 . Endothelial removal resulted in a decreasee of AVP-induced contractile force compared to the vessels incubated withh L-NNA. The fact that the maximal contractile response to KCI was not influencedd by the mechanical removal of the endothelium indicates, that the physiologicall properties of the vascular smooth muscle cells were not affected. Thiss leads to the conclusion that AVP-induced vasoconstriction is partly endothelium-dependent.. The co-release of NO presumably masks this endothelium-dependentt increase in contractile force. PhE could not evoke this effect;; on the contrary, the contractile response was increased in endothelium-denudedd preparations.
Thee interaction between AVP and the endothelium in the renal artery of differentt species has been studied by several authors
. demonstrated in the rabbit renal artery an AVP-induced rise in contractile force,, which dose-dependently increased in the presence of the NO synthase inhibitorr N G -nitro-L-arginine methyl ester (L-NAME) 1-100 uM 14 . These findingss are in accordance with our results observed in the presence of L-NNA 100100 uM. However, the results by Garcia-Villalon et al. in vascular segments withoutt endothelium showed an increase in contractile force. Important to notee is that the combination of L-NAME and endothelium removal resulted in a furtherr elevation of contractile force when compared to the endothelium denudedd vessel segments. A possible explanation, as suggested by the authors,, is that the endothelium in their experiments had not been removed completely.. Katusic et al. have conducted experiments evaluating the effects off AVP on endothelium denuded and endothelium intact vessel segments of thee rat renal artery. They confirmed our results, with respect to comparable contractilee force in intact or endothelium denuded segments 24 . Medina et al.
showedd in human renal arteries a comparable contractile force in the presence orr absence of intact endothelium or in the presence of L-NAME 25 . This suggestss that our results are possibly not translatable to human renal arteries, butt it is important to realise that the data by Medina et al. could have been influencedd by unknown peri-operative factors.
Ourr experiments with the Vi antagonist SR-49059 confirm the conclusion derivedd earlier that AVP-induced vasoconstriction is mediated by Vi receptors i4;i7;25__ As has ^e en discussed in the previous paragraph, vasopressinmediatedd vasoconstriction is caused by direct and indirect (endotheliumdependent)) smooth muscle cell activation. The contractile force mediated directlyy and indirectly by vasopressin, was dose dependently antagonised by thee Vi antagonist SR-49059 and could not be demonstrated by the V 2 agonist desmopressin,, or inhibited by the V 2 antagonist SR-121463 B.
Thee AVP receptor subtype that causes NO release remains controversial. Some authorss suggest that the Vi receptor mediates the AVP induced NO release 26;27 ,, in contrast to others, who submitted the V 2 receptor-induced release of NOO 16;28 . The V 2 antagonist SR-121463 B or the V 2 agonist desmopressin did nott influence our data. This leads to the conclusion that in our experimental set-upp the NO release in the renal artery of the rabbit is mediated by the activationn of the Vi receptor.
Thee role of a possible interaction of endothelium-derived hyperpolarizing factor (EDHF)) and AVP has not been evaluated in the renal artery, but also in this tissuee an interaction can be imagined 29 . Incubation of the vessels with charybdotoxinn does result, in the presence or absence of intact endothelium or L-NNA,, in a comparable increase in contractile force induced by the AVPconcentrationn response curve. Ca 2+ activated K + channels are known to be directlyy involved in processes that regulate the smooth muscle cell tone, as hass been demonstrated in the rat cerebral artery 30 and mesenteric artery 22 .
Thee hypothesis suggested by these authors is that the agonist-induced increasee of intra-cellular Ca 2+ is sufficient to activate the intermediate and largee conductance Ca 2+ activated K + channels. The similarity of the results obtainedd in vessels with intact endothelium with those without endothelium suggestss that the role of EDHF in an interaction with AVP induced contractions iss trivial.
Somee authors reported 31;32 that relaxant prostaglandins are functionally visiblee in the human saphenous vein and the human renal artery. In these experiments,, after precontraction with norepinephrine and in the presence of a Vii antagonist, AVP resulted in vasodilation, which could be partly inhibited by indomethacin.. In our study incubation of the vessels with indomethacin or meclofenamicc acid, did result in a similar outcome compared to the control experiment.. The different experimental set-up and tissue used in our experimentss can explain the dissimilarity in effects between these 31;32 and our results.. These experiments in the presence with indomethacin or meclofenamicc acid showed that the functional effects of lipoxygenase or cyclooxygenasee pathway are limited in the rabbit renal artery and cannot explainn the nature of the endothelium-dependent contractile factor.
Besidess the role of these established interactions, another endothelium dependentt factor can be involved. It has been described that the Endothelin-1 synthesiss and release can be stimulated by AVP 33 " 35 , but the precise role in thee renal circulation under control conditions has not been established. Our resultss show no inhibitory effect on the AVP induced contraction with the ET A andd ET B antagonist bosentan. This excludes a direct functional role for an AVPinducedd endothelin release.
Inn conclusion, our study confirms that AVP is a vasoconstrictor in the isolated renall artery. The vasoconstriction by AVP is mediated by Vi receptors and it is influencedd by both an endothelial dependent vasoconstriction and a LArginine-NOO pathway mediated vasodilation. This contractile effect is independentt of lipoxygenase and cyclooxygenase pathways or endothelins. Furthermore,, the AVP induced contraction appears to be inhibited by an activationn of Ca 2+ activated K + channels.
